Theranexus : Levée de fonds de 3.1 M€
>Visibilité financière étendue jusqu’au T4 2024e - Theranexus a réalisé une augmentation de capital de c. 3.1 M€ au travers de l’émission de 2.4 M d’actions au prix de 1.28 €, soit une décote de 25.8% par rapport au cours de clôture du 10 juillet 2023. Dans le cadre de cette opération, la fondation américaine BBDF (Beyond Batten Disease Foundation) est entrée au capital à hauteur de 11.6%. BBDF et 4 autres investisseurs dont les noms ne sont pas communiqués représente...Theranexus SA is a France-based company engaged in the healthcare industry. The Company is a biopharmaceutical entity that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders, including epilepsy, narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain and psychiatric disorders. Its patented technology is aimed at increasing the efficacy of CNS drugs, which are approved and available on the market. The Company's technology is protected, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes. Theranexus SA operates in the domestic market.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.